Salta al contenuto principale
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
Persone
emilia.scalzulli@uniroma1.it
Emilia Scalzulli
Assegnista di ricerca
Struttura:
DIPARTIMENTO DI MEDICINA TRASLAZIONALE E DI PRECISIONE
E-mail:
emilia.scalzulli@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Pubblicazioni
Titolo
Pubblicato in
Anno
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia
EUROPEAN JOURNAL OF HAEMATOLOGY
2020
A Multicenter Real-Life Study On Anticoagulant Treatment With Direct Oral Anticoagulants In Patients With Ph Negative Myeloproliferative Neoplasms
AMERICAN JOURNAL OF HEMATOLOGY
2020
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
CLINICAL DRUG INVESTIGATION
2020
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience
ANNALS OF HEMATOLOGY
2020
The advantages and risks of ruxolitinib for the treatment of polycythemia vera
EXPERT REVIEW OF HEMATOLOGY
2020
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab
ANNALS OF HEMATOLOGY
2020
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients
ANNALS OF HEMATOLOGY
2020
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice
EXPERT REVIEW OF HEMATOLOGY
2020
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors
ANNALS OF HEMATOLOGY
2020
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. ACampus CMLstudy
BLOOD CANCER JOURNAL
2020
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previousTKIs
AMERICAN JOURNAL OF HEMATOLOGY
2020
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib
HEMATOLOGICAL ONCOLOGY
2020
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience
ANNALS OF HEMATOLOGY
2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance
LEUKEMIA & LYMPHOMA
2020
The advantages and risks of ruxolitinib for the treatment of polycythemia vera
EXPERT REVIEW OF HEMATOLOGY
2020
Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib
BLOOD
2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance
LEUKEMIA & LYMPHOMA
2020
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
THERAPEUTIC ADVANCES IN HEMATOLOGY
2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
HEMATOLOGICAL ONCOLOGY
2019
« prima
< precedente
1
2
3
4
5
seguente ›
ultima »
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma